{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Toxic death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"38"}]}],"title":"No toxic death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Implementation of the toxic death rate stopping rule, a death must be possibly, probably or definitely attributable to Rituximab and/or chemotherapy to be considered a toxic death.","groups":[{"description":"Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.","id":"OG000","title":"Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)"},{"description":"Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.","id":"OG001","title":"Group C (Chemotherapy, Monoclonal Antibody Therapy)"}],"paramType":"NUMBER","populationDescription":"Population analyzed includes eligible patients (Group B:46; Group C: 42). Three additional patients (Group B:1; Group C:2) have been excluded as inevaluable per the study chair.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Toxic Death","type":"PRIMARY","unitOfMeasure":"participants"}